A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection

Cancer Research

Volumn 67, Issue 5, 2007, Pages 2351-2359

  Suzuki, Eiji ^a   Kim, Samuel ^a   Cheung, H Kam ^b   Corbley, Michael J ^b   Zhang, Xiamei ^b   Sun, Lihong ^b   Shan, Feng ^b   Singh, Juswinder ^b   Lee, Wen Cherng ^b   Albelda, Steven M ^a   Ling, Leona E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALK5 INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; SM 16; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOREDUCTIVE SURGERY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; FEMALE; IN VIVO STUDY; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCID MOUSE; SPLEEN; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR REGRESSION;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNITY, CELLULAR; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; PROTEIN KINASE INHIBITORS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 33947246042     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2389     Document Type: Article

References (57)

1. Arteaga CL. Inhibition of TGFβ signaling in cancer therapy. Curr Opin Genet Dev 2006;16:30-7.
2. Pinkas J, Teicher BA. TGF-β in cancer and as a therapeutic target. Biochem Pharmacol 2006;72:523-9.
3. Elliott RL, Blobe GC. Role of transforming growth factor β in human cancer. J Clin Oncol 2005;33:2078-93.
4. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity: implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J Clin Invest 1993;92:2569-76.
5. Bandyopadhyay A, López-Casillas F, Malik SN, et al. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Can Res 2002;62: 4690-5.
6. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastasis. J Clin Invest 2002;109:1551-9.
7. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor β signaling impairs Neuinduced mammary tumorigenesis while promoting pulmonary metastasis. Pro Nat Acad Sci U S A 2003; 100:8430-5.
8. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002;109:1607-15.
9. Won J, Kim H, Park EJ, Hong Y, Kim SJ, Yun Y. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res 1999;59:1273-7.
10. Maggard M, Meng L, Ke B, Allen R, Devgan L, Imagawa DK. Antisense TGF-β2 immunotherapy for hepatocellular carcinoma: treatment in a rat tumor model. Ann Surg Oncol 2001;8:32-7.
11. Witham TF, Villa L, Yang T, et al. Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J Neurooncol 2003;64:63-9.
12. Uhl M, Aulwurm S, Wischhusen J, et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004;64:7954-61.
13. Ling LE, Singh J, Chuaqui CE, et al. The use of virtual screening in ALK5 kinase inhibitor discovery and validation of orally active ALK5 kinase inhibitors in oncology. In: Jakowlew S, ed. Transforming growth factor-β in cancer therapy. In: Teicher B, series ed. Cancer Drug Discovery and Development. Totowa: Humana Press. In press.
14. Marzo AL, Fitzpatrick DR, Robinson BW, Scott B. Antisense oligonucleotides specific for transforming growth factor β2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997;57:3200-7.
15. Suzuki E, Kapoor V, Cheung HK, et al. Soluble type II transforming growth factor-β receptor inhibits both small and large established murine malignant mesothelioma tumor growth by augmenting host anti-tumor immunity. Clin Cancer Res 2004;10:5907-18.
16. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signaling inhibitors for cancer therapy. Nat Rev 2004;3:1011-22.
17. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
18. Lammerts E, Roswall P, Sundberg C, et al. Interference with TGF-β1 and -β3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma. Int J Cancer 2002;102:453-62.
19. Maeda J, Ueki N, Ohkawa T, et al. Transforming growth factor-β1 (TGF-β1)- and β2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer. Clin Exp Immunol 1994;98:319-22.
20. DeLong P, Carroll RG, Henry AC, et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 2005;4:342-6.
21. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, et al. Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Cytokine Growth Factor Rev 2006;17:129-39.
22. Singh J, Ling LE, Sawyer JS, Lee WC, Zhang F, Yingling JM. Transforming the TFGβ pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TβRI (ALK5). Curr Opin Drug Discov Devel 2004;7:437-45.
23. Bonniaud P, Margetts PJ, Kolb M, et al. Progressive transforming growth factor β1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 2005;171:889-98.
24. de Gouville AC, Boullay V, Krysa G, et al. Inhibition of TGF-β signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol 2005;145:166-77.
25. Moon JA, Kim HT, Cho IS, et al. IN-1130, a novel transforming growth factor-β type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006;70:1234-43.
26. Ge R, Rajeev V, Ray P, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type 1 receptor kinase in vivo. Clin Cancer Res 2006;12:4315-30.
27. Muraoka-Cook RS, Shin I, Yi JY, et al. Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 2006;25:3408-23.
28. Singh J, Chuaqui CE, Boriack-Sjodin PA, et al. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI). Bioorg Med Chem Lett 2003;13:4355-9.
29. Odaka M, Sterman D, Wiewrodt R, et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-β gene therapy due to induction of systemic immunity. Cancer Res 2001;61:6201-12.
30. Fitzpatrick DR, Bielefeldt-Ohman H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BWS. Transforming growth factor-β: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity, and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994;11:29-44.
31. Winn HJ. In vivo methods for the assessment of antibody-mediated tumor immunity. Natl Cancer Inst Monogr 1972;35:13-8.
32. DeLong P, Tanaka T, Kruklitis R, et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003;63:7845-52.
33. Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005;10:266-83.
34. Dumont N, Arteaga CL. Targeting the TGFβ signaling network in human neoplasia. Cancer Cell 2003;3:531-6.
35. Trapani JA. The dual adverse effects of TGF-β secretion on tumor progression. Cancer Cell 2005;8:349-50.
36. Thomas DA, Massague J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8:369-80.
37. Shah AH, Tabayoyong WB, Kundu SD, et al. Suppression of tumor metastasis by blockade of transforming growth factor β signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res 2002;62:7135-8.
38. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med 2001;10:1118-22.
39. Ahmadzadeh M, Rosenberg SA. TFG-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 2005;174:512-23.
40. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11:5515-25.
41. + regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res 2002;62:5267-72.
42. Riccobon A, Gunelli R, Ridolfi R, et al. Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes. Cancer Invest 2004;22:871-7.
43. Von Bernstorff W, Voss M, Freichel S, et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin. Cancer Res 2001;7:925-32s.
44. + T cells: eradication of autologous mouse prostate cancer. Cancer Res 2005;65:1761-9.
45. Hsieh CL, Chen DS, Hwang LH. Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum Gene Ther 2000;11:681-92.
46. Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 2000;164:2214-20.
47. Kruklitis RJ, Singhal S, DeLong P, et al. Immuno-gene therapy with interferon-β before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma J Thorac Cardiovasc Surg 2004;127:123-30.
48. Oft M, Heider KH, Beug H. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998;8:1243-52.
49. Wojtowicz-Praga S, Verma UN, Wakefield L, Esteban JM, Hartmann D, Mazumder A. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor β antibody and interleukin-2. J Immunother Emphasis Tumor Immunol 1996;19:169-75.
50. Steller MD, Shaw TJ, Vanderhyden BC, Ethier JF. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol Cancer Res 2005;3: 50-61.
51. Landis MD, Seachrist DD, Montanez-Wiscovich ME, Danielpour D, Keri RA. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-β signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene 2005; 24:5173-90.
52. Di Simone N, Crowley WF, Jr., Wang QF, Sluss PM, Schneyer AL. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 1996;137:486-94.
53. Choi KC, Kang SK, Nathwani PS, Cheng KW, Auersperg N, Leung PC. Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal and neoplastic ovarian surface epithelium (OSE). Mol Cell Endocrinol 2001;174:99-110.
54. Wagner K, Peters M, Scholz A, Benckert C, Ruderisch HS, Wiedenmann B, Rosewicz S. Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells. Gastroenterology 2004;126:1828-43.
55. Wildi S, Kleeff J, Maruyama H, Maurer CA, Buchler MW, Korc M. Overexpression of activin A in stage IV colorectal cancer. Gut 2001;49:409-17.
56. Ito I, Minegishi T, Fukuda J, Shinozaki H, Auersperg N, Leung PC. Presence of activin signal transduction in normal ovarian cells and epithelial ovarian carcinoma. Br J Cancer 2000;82:1415-20.
57. Kleeff J, Ishiwata T, Friess H, Buchler MW, Korc M. Concomitant over-expression of activin/inhibin β subunits and their receptors in human pancreatic cancer. Int J Cancer 1998;77:860-8.